4.7 Article

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 63, 期 20, 页码 11368-11396

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00249

关键词

-

资金

  1. Natural Science Foundation of Jiangsu Province [BK20141349]
  2. China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs [2013ZX09301303-002]

向作者/读者索取更多资源

SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally, SHP2 serves as an important hub to connect several intracellular oncogenic signaling pathways, such as Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1 pathways. Mutations and/or overexpression of SHP2 has been associated with genetic developmental diseases and cancers. Because of the role of SHP2 plays in many diseases, the development of inhibitors targeting the catalytic site in SHP2 has been pursued for more than a decade, but none has advanced to clinical development. Recent discovery of allosteric inhibitors has inspired a novel approach to selectively target SHP2 via the noncatalytic site. To date, four SHP2 allosteric inhibitors have entered clinical trials for the treatment of solid tumors. This review will provide a summary of the physiological and biological functions of SHP2 and discuss the development of nonallosteric/allosteric SHP2 inhibitors in recent years.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据